Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative recovery with long-acting NK1 and 5-HT3 antagonists for PONV prophylaxis in laparoscopic surgery
2025-522529-36-00Phase 3Authorised
- Sponsor
- Region Vaesternorrland, Umea University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palonosetron, fosaprepitant and ondansetron in postoperative nausea and vomiting (PONV) (3 arms), sponsored by Region Vaesternorrland, Umea University. Primary endpoint: Change in QoR-15swe score from preoperative baseline to postoperative day 1. Planned start Dec 2025; status: authorised.
02
Drugs
palonosetronfosaprepitantondansetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2025-522529-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522529-36-00.